LivaNova is a pioneering global medical technology company focused on developing innovative therapies to transform lives. Our portfolio of life-changing technologies spans the areas of neuromodulation and cardiovascular diagnosis and treatment. We aim to improve the health and quality of life of the communities we serve.
LivaNova PLC operates at the forefront of medical technology with a major focus on improving patient outcomes. LivaNova's innovative medical technologies and commitment to excellence make us leaders in the fields of cardiovascular and neuromodulation. Our products and treatments are designed to benefit not only individual patients but also the broader healthcare systems serving them.
At LivaNova, therapeutic advancement is the core of what we do. We focus on heart and neurological conditions, offering cardiopulmonary devices, neuromodulation technologies, and several other transformative medical devices designed to treat Obstructive Sleep Apnea and Drug-Resistant Epilepsy. We are committed to extending and enhancing life by advancing therapies that cater to diverse medical conditions.
Guided by our ethical obligations and corporate responsibility, LivaNova vigorously pursues sustainability goals. We work diligently to minimize our environmental footprint, ensure the highest standards of corporate governance, and embody the highest ethical standards to make a positive social impact.
Join LivaFor professionals looking to make a tangible impact on the world, LivaNova is the place to be. Our team is filled with passionate individuals dedicated to innovation and excellence in the field of medical technology. Explore career opportunities with us where you can help make a difference in enhancing global health.
To learn more about our groundbreaking medical devices and therapies or to explore potential collaborations, please visit our main office at 20 Eastbourne Terrace, London, or reach out via our contact page. Join us in our mission to transform lives through ground-breaking medical technology at LivaNova.